TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸AGIO

Agios Pharmaceuticals, Inc. - Common Stock

NASDAQ
$29.68
▼ $1.64 (-5.2%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 18 Nov 2026
H $44.09L $26.44+3.2%
$44.09$40.56$37.03$33.5$29.97$26.44$29.68
RSI (14)
Intraday · 15-minBuy+15RSI 55SidewaysMACD Bullishfor day-trading context — not advice

Technical signal

Strong sell-60
RSI (14)41
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$27.57
Resistance
$38.69
  • Price is below its 50-day average (medium-term weakness).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest · 2026-02-18 → 2026-11-18

Strategy return
-26.4%
Buy & hold
+7.7%
Trades
7
Win rate
14%

$100,000.00 invested would be worth $73,558.94 (-26.4%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Agios Pharmaceuticals, Inc.· Biotechnology

source: yahoo

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Employees
539
Headquarters
Cambridge, United States
www.agios.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:▲ Positive1↑ · 0↓ · 7–
  • Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run— Neutral
    Simply Wall St. · 07 Nov 2026
  • Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x on ...▲ Positive
    GuruFocus.com · 06 Nov 2026
  • BofA Securities Adjusts Agios Pharmaceuticals Price Target to $48 From $50— Neutral
    MT Newswires · 06 Nov 2026
  • Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
— Neutral
Moby · 05 Nov 2026
  • What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call— Neutral
    MarketBeat · 05 Nov 2026
  • Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates— Neutral
    Zacks · 05 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.